A director at CRISPR Therapeutics AG bought 989,812 shares at 52.030USD and the significance rating of the trade was 98/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...
Shenandoah Telecommunications Company to Hold its Second Quarter 2025 Earnings Call at 4:30 p.m. on Thursday, July 31, 2025. EDINBURG, Va., July 17, 2025 (GLOBE NEWSWIRE) -- Shenandoah Telecommunications Company (Shentel) (NASDAQ:SHEN) will release its second quarter 2025 financial results after the market closes on Thursday, July 31, 2025, and will host a conference call and simultaneous webcast on the same day at 4:30 p.m. Eastern Time to discuss Shentel’s financial results and business highlights. Date: July 31, 2025Time: 4:30 PM ET Listen via Internet: For Analysts, please registe...
Wag! Group Co. Announces Sale of Furscription to MWI Veterinary Supply Co. Transaction Reflects the Board’s Ongoing Strategy to Maximize Shareholder Value SAN FRANCISCO, July 15, 2025 (GLOBE NEWSWIRE) -- Wag! Group Co. (“Wag!”; Nasdaq: PET), which strives to be the number one platform to solve the service, product, and wellness needs of the modern U.S. pet household, announced today that it has simultaneously entered into a definitive agreement (the “Agreement”) and completed the sale of its Furscription business to MWI Veterinary Supply Co. (“MWI”), a leading global provider of veterin...
Glo Fiber Expands High-Speed Fiber Optic Internet in York County, PA Broadband speeds up to 5 Gbps will be available in Hallam Borough, Hellam Township and Wrightsville Borough, Pennsylvania EDINBURG, Va., July 15, 2025 (GLOBE NEWSWIRE) -- Glo Fiber, powered by Shenandoah Telecommunications Company (“Shentel”) (Nasdaq: SHEN), announced they have reached agreements to deploy fiber-to-the-home (FTTH) broadband services to Hallam Borough, Hellam Township and Wrightsville Borough in York County, Pennsylvania. Glo Fiber will bring their future-proof, 100% fiber network to over 2,000 homes an...
Glo Fiber Expanding High-Speed Fiber Optic Internet in Frederick County, MD Broadband speeds up to 5 Gbps will be available in the towns of New Market and Walkersville, Maryland EDINBURG, Va., July 08, 2025 (GLOBE NEWSWIRE) -- Glo Fiber, powered by Shenandoah Telecommunications Company (“Shentel”) (Nasdaq: SHEN), announced they have reached an agreement to deploy fiber-to-the-home (FTTH) broadband services to over 2,600 additional homes in Frederick County, Maryland in the towns of New Market and Walkersville. Glo Fiber’s future-proof, reliable high-speed internet service is already ava...
Glo Fiber Launches Lightning-Fast Fiber Internet in Hillsboro, Ohio EDINBURG, Va., July 02, 2025 (GLOBE NEWSWIRE) -- Glo Fiber, powered by Shenandoah Telecommunications Company (“Shentel”) (Nasdaq: SHEN), has launched their 100% fiber optic broadband service in initial neighborhoods in Hillsboro, Ohio. Construction began earlier this year and is expected to be completed in early 2026, providing over 3,000 homes and businesses with a reliable, future-proof option for high-speed internet service. As construction continues, residents will receive advance notice via mail, and they can check a...
CRISPR Therapeutics Named to TIME’s Most Influential Companies List of 2025 ZUG, Switzerland and BOSTON, June 30, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, has been named to the fifth annual list. The Company was recognized in the Pioneers category for its groundbreaking work in advancing the field of gene editing. TIME highlighted CRISPR Therapeutics’ expansion beyond its landmark success in treating sickle cell disease and beta thalassemia, noting the Company’s...
CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310™ Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline -New Phase 1 clinical data for CTX310™ continues to demonstrate dose-dependent reductions in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 86% in LDL, with a well-tolerated safety profile- -Complete Phase 1 data presentation for CTX310 anticipated at a medical meeting in the second half of 2025- -Data update for CTX320™, targeting the LPA gene, now expected in the first half of 2026- -Pre...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.